Document is current

Article History

Received: 1 July 2024

Accepted: 18 December 2024

First Online: 8 January 2025

Declarations

:

: C.C. consulting/advisory role/speaker bureau: Pfizer, Roche, MSD, Lilly, Novartis, Seagen, Gilead, AstraZeneca, Daiichi Sankyo. A.M. has received honoraria as a consultant, advisor or speaker from Roche and Menarini/Stemline; and has received travel and accommodation support from AstraZeneca. G.C. received honoraria for speaker’s engagements from Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, and MSD; honoraria for providing consultancy from Roche, Seattle Genetics, and NanoString; honoraria for participating in Advisory Board for Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, and Mylan; honoraria for writing engagement from Novartis and BMS; honoraria for participation in Ellipsis Scientific Affairs Group; Institutional research funding for conducting phase I and II clinical trials from Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, and Medimmune. The other authors have no relevant financial or non-financial interests to disclose.

: Not Applicable.

: Not Applicable.

: Not Applicable.